Issues

In this month's edition, Bennett and colleagues disclose BT5528, a Bicycle toxin-conjugate targeting EphA2. On the cover, BT5528 is shown bound to EphA2 on the surface of HT1080 fibrosarcoma cells in a High Content Screening assay. BT5528 provided persistent toxins to tumor cells while avoiding systemic exposure and has entered a Phase I clinical trial (NCT04180371). Read the First Disclosure on page 1385.